rofecoxib has been researched along with Atrophy in 1 studies
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rofecoxib causes regression and atrophy of the endometriotic lesions and is as effective as a GnRH agonist with an accompanying decrease in the VEGF levels." | 3.72 | Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. ( Altunyurt, S; Caliskan, S; Dogan, E; Posaci, C; Saatli, B; Saygili, U; Tuna, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dogan, E | 1 |
| Saygili, U | 1 |
| Posaci, C | 1 |
| Tuna, B | 1 |
| Caliskan, S | 1 |
| Altunyurt, S | 1 |
| Saatli, B | 1 |
1 other study available for rofecoxib and Atrophy
| Article | Year |
|---|---|
Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib.
Topics: Administration, Oral; Animals; Ascitic Fluid; Atrophy; Cyclooxygenase Inhibitors; Endometriosis; Fem | 2004 |